GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top ResearchGLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top Research
(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes. In a phase III trial… (MedPage Today) — As part of a longevity push, telehealth company Noom is Read More
First she got breast cancer. Then her daughter did, tooFirst she got breast cancer. Then her daughter did, too
A breast cancer diagnosis is hard enough – what happens when a mother and daughter go through it at the same time?Genna Freed should have been in the mood to celebrate. On a cloudy November day in 2022, her mother, Julie Newman, was about to complete her final round of radiation, after being diagnosed with breast cancer in September. The whole family, a close-knit bunch, was gathering with balloons and signs.But Freed, then a few weeks shy of her 31st birthday, was carrying a secret. Spurred by her mother’s diagnosis, she had her first mammogram a couple days earlier, and it had turned up a suspicious spot. Now she needed a second, diagnostic mammogram, and likely a biopsy. She found herself walking a surreal sort of tightrope, caught between relief that her mother’s treatment was over and fear that she might soon be starting her own. Continue reading…
AI Model Stratifies Late Recurrence Risk in HR-Positive Breast CancerAI Model Stratifies Late Recurrence Risk in HR-Positive Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask deep-learning algorithm that aims to estimate late distant recurrence risk in hormone receptor (HR)-positive breast…
Time Burden in Patients With Metastatic Breast and Ovarian CancerTime Burden in Patients With Metastatic Breast and Ovarian Cancer
This cohort study evaluates time demands among patients with metastatic breast and ovarian cancer.
Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast CancerBlockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer
(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results…
Awareness of BRCA Status Drives Aggressive Surgery in Early-Onset Breast CancerAwareness of BRCA Status Drives Aggressive Surgery in Early-Onset Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators from an international consortium reported that knowledge of BRCA1/2 mutation status strongly influenced surgical decision-making in young patients with stages I-III breast…
Preop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast CancerPreop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation and tumor response in node-positive hormone receptor-positive (HR+)/HER2-negative breast cancer…
No Increased Breast Cancer Risk With Menopausal Estrogen in BRCA CarriersNo Increased Breast Cancer Risk With Menopausal Estrogen in BRCA Carriers
(MedPage Today) — SAN ANTONIO — Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here.
In fact, women who used estrogen-only MHT had a significantly lower risk…
How Were GLP-1 Drugs and Bone Health Linked?How Were GLP-1 Drugs and Bone Health Linked?
(MedPage Today) — You passed medical training, now see if you can pass our weekly quiz (MedPage Today) — You passed medical training, now see if you can pass our weekly quiz
Ozempic may offer a surprising bonus benefit for brain healthOzempic may offer a surprising bonus benefit for brain health
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous Read More